Cepheid Reports 2009 Second Quart...(Accounts receivable ...),Health

Date:7/30/2009

Accounts receivable (1,876) 2,690 Inventory (1,925) (4,419) Prepaid expenses and other current assets 2,018 (1,239) Other non-current assets 426 (161) Accounts payable and other current liabilities 2,282 5,120 Accrued compensation 267 (210) Deferred revenue 6 (1,348) --- ------- Net cash provided by operating activities 1,724 4,564 ----- ----- Cash flows from investing activities: Capital expenditures (2,823) (8,712) Payments for technology licenses (1,500) - Cost of acquisition, net (148) - Proceeds from maturities of marketable securities and short-term investments 25 2,550 Proceeds from the sale of fixed assets 15 125 Transfer to unrestricted cash 1,500 517 ----- --- Net cash used in investing activities (2,931) (5,520) ------- ------- Cash flows from financing activities: Net proceeds from the issuance of common shares and exercise of stock options and awards 2,383 9,333 Principal payments of bank borrowing (40) - Principal payments of notes payable - (4) ---
'/>"/>

SOURCE Cepheid Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
2. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
3. Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA
4. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
5. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
6. Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
7. Cepheid Reports Record Revenue of $44.8 Million
8. Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
9. Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
10. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
11. Cepheid Reports Fourth Quarter and Full Year 2008 Results